Søren Tulstrup, President and CEO, Hansa Biopharma said, “We know that anti-AAV antibodies prevent up to 1 in 3 people from benefitting from gene therapies using AAV-vectors. 1-4 That’s why our ...
A cancer therapy that prompts the body's immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke.
#1 Most Recognized Public University in the U.S. American Caldwell, 2024 Take your photo with the alumnus depicted as he was during his undergraduate days: ready to go with a stack of books and a ...